Monopar Therapeutics (MNPR) logo

Monopar Therapeutics (MNPR) stock

Medicines for disease , market cap $476M

After-hours Fri
$67.35
-2.40%

Close $69.00 -1.84%

Quality Score
-4
Poor
In its industry
#170of 273
Checks firing
2of 14
Transition
From 52-week high
-44.7%
under its best in a year

MNPR's Quality Score rose 1 point on Fri, Nov 20, to -4. It had its calmest day in a week.

Follow MNPR's trial news. Pro members can get an alert when Monopar Therapeutics files news, and see its trials, share raises, and its CEO's filings.

Get an alert when MNPR files news on its trialsSee it live, free until Tuesday morning. No account. No card.One stock in full, free. No account.$1 for a first month of Pro. Then $39 a month. Then keep going with a free account.Then $1 for a first month of Pro.Then 7 days of Pro free, with a card.

We do the work for you. Every stock is scored and ranked, every 15 seconds while the market is open. Here it's 15 minutes behind. Pro members see it live.

Cash$105M, Over 5 years at the last year's spendingOn Sep 30

Why is MNPR down?

Down 38% in 3 months while the S&P 500 fell 10%.

  • Its share count rose 20.2% in a year, so each share is a smaller slice of the company.

Sources: Price history, Nov 20, 2026; Quarterly reports, Sep 30, 2026

−2Long-term trend below a falling 200-day average, down over one year

1 more reason, free with an account →See every reason on MNPR →The other side, how the business stands, the timeline, and its peers, for Pro members.

Key facts on MNPR

Key facts on MNPR
Holding it backA $21M loss wider than $19M a year earlier
Latest filing8-K, Nov 12 Reported its quarterly results

Tested. Our top-scored stocks returned 2.2x the average stock over the next month. Reconstructed after the fact; recorded live since Sep 9, 2026. How we tested it

Cash$105M, Over 5 years at the last year's spendingOn Sep 30

MNPR catalysts

Coming up

After its last 4 reports it closed -1.7% on average, higher 1 of 4 times.

3 past catalysts since 2026, with sizes and sources, for Pro members.

What's next for MNPR, and how long its cash lasts

Its trials

A trial underway
Diagnostic Efficacy and Dosimetry of MNPR-101-DFO*-89Zr in Patients With Solid TumorsPhase 1 · Active · 12 people · main data estimated Dec 2026 · NCT06337084

1 more trial, 50 filings, for Pro members.

Cash runway Sep 30 balance sheet

Over 5 years

$105M in cash and short-term investments, at its spending over the last year

What it means: how long the cash would last at the same pace, before any new money.

For Pro members: the cash used each quarter, and the math.

Dilution on the horizon

  • Shelf registration (S-3, filed Aug 29, 2025)

For Pro members: 3 raises and their amounts, and the share count against a year ago.

Insiders

Director Kim R. Tsuchimoto sold 4,090 shares on Nov 4, under a planned sale. 5 more insider trades this year.

From Form 4: open-market buys and sales only.

For Pro members: every trade, and Chandler Robinson’s 21 filings and quotes.

Get an alert when MNPR files news on its trialsA free account. No card.Pro: $1 first month.Pro, 7 days free with a card.

See every upcoming FDA date →

FDA dates in the next 60 days

Decision dates and advisory committee meetings the companies have announced in their filings, soonest first and small companies first.

DateStockDrug

12 more FDA dates and 98 trial data dates in the next 60 days, each on the FDA calendar. Pro members see whether each company's cash lasts past its date, with an optional alert before it. See all 144 dates, ranked →See all 144 dates, ranked →Start Pro

How MNPR ranks in Biotech

MNPR is #170 of 273 by Quality Score.

How MNPR ranks in Biotech
RankStockQuality Score
170Monopar Therapeutics (MNPR) logoMNPRMonopar Therapeutics-4

More in Biotech

When does MNPR report earnings, and what happens after?

Expected to report Thu Mar 18, before the open (in 117 days).

What an earnings report is: every 3 months, a company tells everyone how much it sold and earned. We read the figures, the outlook, and how the stock moved after.

What MNPR reported on Nov 12, 2026

The quarter

The figures are not read from the release yet.

“The increase is attributed to interest earned on U.S. Treasury securities and commercial paper and to higher bank balances in 2026 due to the net proceeds of approximately $91.9 million from the September 2025 capital raise.”

The filing on EDGAR

Where the sales came from

MNPR's results filing gives no sales by line in a table we read.

The outlook

No outlook figures read from this release.

In the company's words

  • “Monopar expects its current funds to support operations through at least March 31, 2028, including: (1) regulatory and potential commercial activities for ALXN1840; (2) continued development of MNPR-101 programs; and (3) internal research and development.”

From its results filing (SEC filing · Nov 12)

The numbers

Market value
$476M
today

No analyst estimates on Breakaway: every figure here is filed.

The whole report on MNPR: every line of its sales, every outlook beside the one it replaced, and the company's words, for Pro members.

Close after the report, last 3

-2.8%-3.9%+1.3%
May 14Aug 12Nov 12
ReportedGapReaction5
days
Nov 12, 2026Before open-2.3%+1.3%-1.4%
Aug 12, 2026No time given-4.1%-3.9%+7.8%
May 14, 2026No time given-2.2%-2.8%+2.8%

MNPR closed higher after 1 of its last 4 reports.

All 4 reports, and MNPR's Quality Score going into each

MNPR sales and profit by year

Profit by year

Sales fell every year from 2016 to 2025, to $0. It lost money in each of the six years.

MNPR has 2 of 14 chart checks firing

Volume1 of 3 shown
Tight range1 of 3 shown
Buying1 of 3 shown
The other 10 checks on MNPR, and all 14 on every stock.Get in free →See the top 3 →Start Pro

MNPR RSI on Nov 20: 39.9, below its 50-day and 200-day averages

Not scored

RSI 39.9, MACD above signal, below both averages. Not scored.

MNPR share count over time

20% more shares than a year earlier.

Weighted shares, quarter to Sep 30, 2026, both from one filing

Shares of MNPR outstanding, as filed
Shares
outstanding
As
of
6.78MOct 31, 2026
6.71MJul 31, 2026
6.7MApr 30, 2026
6.69MMar 17, 2026
Offerings, shelves, and splits of MNPR, from its filings
From its
filings
Filed
Raised $70M in a sale of shares, about 15% of its market valueSep 24, 2025
Registered shares for a later sale (S-3)Aug 29, 2025
Registered shares for a later sale (S-3)Jan 15, 2025
Raised $799 in a sale of sharesDec 23, 2024

MNPR's officers and directors

Officers and directors with a Form 4 in the last 12 months.

See insider trades by person

Which ETFs hold MNPR?

In ETFs: MNPR is under 0.1% of VTI, the most of the 24 funds Breakaway covers, by their holdings as filed for Jun 30, 2026.

About Monopar Therapeutics

Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company developing a treatment for Wilson disease and novel radiopharmaceuticals for oncology. Its Wilson disease product candidate is ALXN1840, a late-stage, investigational once-daily, oral medicine. The group radiopharmaceutical programs consist of Phase 1-stage MNPR-101-Zr for imaging cancers, and Phase 1a-stage MNPR-101-Lu and late preclinical-stage MNPR-101-Ac for the treatment of cancers that express urokinase plasminogen activator receptor (uPAR). It build drug development pipeline through both in-house efforts and licensing of late preclinical- and clinical-stage therapeutics. The Company operates as a single reportable segment, focusing on the development of clinical and preclinical product candidates.

22 employeesWilmette, ILmonopartx.com

Here is what Pro members see.

  • The same page for Pro members, on Microsoft

    Its Quality Score and rank, the line that drives it, and the live price.

  • The full chart

    A year of candles to start, out to the whole history, with insider trades marked and the Quality Score under the price.

  • Every line of the score

    Price action, the company, and signals, each with its points, on MNPR and every other stock.

  • FDA dates, counted down

    Each date in the company's words, its cash against the date, and an optional alert before it.

  • CEOs buying their own stock

    Every CEO buy, biggest names first. Sort, filter, save the list, and set optional alerts.

  • Congress trades

    A member's trades, newest first, each with its amount. Sort and filter the whole list.

  • 14 chart checks, read for you

    The ones firing on the stock, each in plain words, its rule a tap away.

  • Earnings, week by week

    Who reports each day, and how each stock took its last four reports.

  • The market map

    Every stock a box, colored by its Quality Score.

  • Themes, ranked live

    Each theme's stocks ranked by Quality Score, live. Here, AI chips.

  • The top 10, every day

    The ten highest Quality Scores at each close, kept day by day, week by week.

  • Optional alerts, your way

    Pick a stock, a score, a price, a filing, or a whole scan. It tells you by push or email.

  • Your watchlist, scored

    Your stocks by Quality Score, today's move, or name.

  • On your phone and your laptop

    The same account and watchlist on both, each laid out for its screen.

  • Prices refresh every 2.5 seconds during market hours.
  • Optional alerts by push, email, or the bell.
  • Add it to your Home Screen and it opens like an app.

Pro members see every line of every stock's score.

  • What would turn MNPR's score around: 8 things
  • 8 more filings explained, a plain line each
  • 4 more things pulling MNPR's score down

See it live, free until Tuesday morning. No account. No card.One stock in full, free. No account.$1 for a first month of Pro. Then $39 a month. Then keep going with a free account.Then $1 for a first month of Pro.Then 7 days of Pro free, with a card.

Straight AnswersStraight Answers

As of Nov 21, 2026: MNPR's Quality Score is -4 (Poor), #170 of 273 in Biotech.

What does MNPR's Quality Score say?

MNPR scores -4 today, which Breakaway calls Poor. It is #170 of 273 in Biotech by Quality Score, with 2 of 14 chart checks firing. Down 38% in 3 months while the S&P 500 fell 10%. Cash lasts over 5 years at its spending (to Sep 30). Breakaway does not say whether to buy any stock: the score does not know your situation, and it is not a recommendation to buy or sell anything. Please do your own research.

What is MNPR's Quality Score?

MNPR scores -4 today, which Breakaway calls Poor (below zero). That is #170 of 273 in Biotech by Quality Score. The score adds up the chart checks, the trend, the company's filed sales, its profits, the news, insider trades, and Congress trades. The section above lists the lines behind MNPR's -4.

When does MNPR report earnings?

Expected to report Thu Mar 18, before the open, a date Breakaway expects from the company's usual timing; the company has not confirmed it. MNPR closed higher after 1 of its last 4 reports. Past behavior, not a forecast.

Are the prices delayed?

Only on the public pages, which run at least 15 minutes behind. Pro members, and anyone on a guest pass, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.

Only on the public pages, which run at least 15 minutes behind. Pro members see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included. The one stock you open in full is live too.

Every US stock, ranked live.

Insider and Congress trades, the chart, and the financials, in one score.

See all 3,170 stocks rankedSee all 3,170 stocks rankedStart Pro

See it live, free until Tuesday morning. No account. No card.One stock in full, free. No account.$1 for a first month of Pro. Then $39 a month. Then keep going with a free account.Then $1 for a first month of Pro.Then 7 days of Pro free, with a card.

What's next for Monopar Therapeutics: from its SEC filings and ClinicalTrials.gov, the company's words, the registry's dates, and arithmetic, not a forecast. Companies often miss the dates they set.

The moves after past earnings reports are past behavior, not a forecast.

The price, the score, the chart checks and readings, and the industry rank on this page are delayed at least 15 minutes.

Our top-scored stocks' record: Oct 2021 to Sep 2026, before costs. Recorded live since Sep 9, 2026.

Breakaway publishes impersonal securities research and analytical tools: one formula, the same score for everyone. It is not personalized investment advice, and nothing here is a recommendation to buy or sell any security.

Market data from a licensed vendor. The age of every quote is shown on the page.

This browser is too old to show this page right. Update it, or open this page in Safari or Chrome.